Literature DB >> 16516547

Neuropathy, axonal Na+/K+ pump function and activity-dependent excitability changes in end-stage kidney disease.

Arun V Krishnan1, Richard K S Phoon, Bruce A Pussell, John A Charlesworth, Hugh Bostock, Matthew C Kiernan.   

Abstract

OBJECTIVE: To investigate the mechanisms underlying peripheral neuropathy and to provide insights into axonal Na(+)/K(+) pump function in patients with end-stage kidney disease (ESKD).
METHODS: Nerve excitability was assessed in 10 ESKD patients before and after a single session of haemodialysis and in 29 age-matched control subjects. Changes in excitability were recorded at baseline and following maximal voluntary contraction (MVC) of abductor pollicis brevis (APB) for 60s. Serum concentrations of putative neurotoxins including potassium, urea, parathyroid hormone and beta-2-microglobulin were also measured.
RESULTS: Baseline excitability values were consistent with axonal depolarisation prior to dialysis. Following maximal voluntary contraction (MVC), there was an increase in threshold, which was associated with reduced strength-duration time constant and increased superexcitability, consistent with axonal hyperpolarisation. These changes were quantitatively similar for patients and controls, arguing against any significant reduction in the axonal Na(+)/K(+) pump in ESKD. Following dialysis, activity-dependent changes were less in ESKD, which suggests greater Na(+)/K(+) pump activity prior to dialysis, the opposite of the changes expected with reduced Na(+)/K(+) pump function. The reduced post-contraction threshold change in post-dialysis recordings is likely to be secondary to relative hyperpolarisation of the axonal membrane following dialysis and reduction in K(+) concentration.
CONCLUSIONS: Our findings suggest that Na(+)/K(+) pump function is not impaired in patients with ESKD. SIGNIFICANCE: Pre-dialysis excitability changes in ESKD patients may be explained on the basis of hyperkalaemia. Alteration in Na(+)/K(+) pump function does not appear to be a contributing factor to the development of neuropathy in ESKD patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16516547     DOI: 10.1016/j.clinph.2006.02.002

Source DB:  PubMed          Journal:  Clin Neurophysiol        ISSN: 1388-2457            Impact factor:   3.708


  6 in total

Review 1.  Current and Emerging Pharmacotherapeutic Interventions for the Treatment of Peripheral Nerve Disorders.

Authors:  Jeremy Chung Bo Chiang; Ria Arnold; Roshan Dhanapalaratnam; Maria Markoulli; Arun V Krishnan
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-15

2.  Chronic kidney disease and peripheral nerve function in the Health, Aging and Body Composition Study.

Authors:  Ranjani N Moorthi; Simit Doshi; Linda F Fried; Sharon M Moe; Mark J Sarnak; Suzanne Satterfield; Ann V Schwartz; Michael Shlipak; Brittney S Lange-Maia; Tamara B Harris; Anne B Newman; Elsa S Strotmeyer
Journal:  Nephrol Dial Transplant       Date:  2019-04-01       Impact factor: 5.992

3.  Voxel-based morphometry and arterial spin labeling fMRI reveal neuropathic and neuroplastic features of brain processing of itch in end-stage renal disease.

Authors:  Alexandru D P Papoiu; Nichole M Emerson; Tejesh S Patel; Robert A Kraft; Rodrigo Valdes-Rodriguez; Leigh A Nattkemper; Robert C Coghill; Gil Yosipovitch
Journal:  J Neurophysiol       Date:  2014-06-18       Impact factor: 2.714

Review 4.  Neurological complications of chronic kidney disease.

Authors:  Arun V Krishnan; Matthew C Kiernan
Journal:  Nat Rev Neurol       Date:  2009-09-01       Impact factor: 42.937

5.  Sustained maximal voluntary contraction produces independent changes in human motor axons and the muscle they innervate.

Authors:  David A Milder; Emily J Sutherland; Simon C Gandevia; Penelope A McNulty
Journal:  PLoS One       Date:  2014-03-12       Impact factor: 3.240

6.  Potassium and the excitability properties of normal human motor axons in vivo.

Authors:  Delphine Boërio; Hugh Bostock; Romana Spescha; Werner J Z'Graggen
Journal:  PLoS One       Date:  2014-06-03       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.